home / stock / lexxw / lexxw news


LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 06/29/21

Stock Information

Company Name: Lexaria Bioscience Corp. Warrant
Stock Symbol: LEXXW
Market: NASDAQ
Website: lexariabioscience.com

Menu

LEXXW LEXXW Quote LEXXW Short LEXXW News LEXXW Articles LEXXW Message Board
Get LEXXW Alerts

News, Short Squeeze, Breakout and More Instantly...

LEXXW - Lexaria Announces 2021 Annual Meeting Results

KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2021 Annual Meeting (the 'Meeting'). On June 28, 2021 at 1:00 p.m. (Pacific Time)...

LEXXW - Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs

(TheNewswire) DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 Kelowna, British Columbia - TheNewswire - June 15, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) ...

LEXXW - Lexaria Provides Progress Report on Six R&D Programs

All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine These studies are part of Lexaria's 2021 applied R&D program intended to enable opportunities for strategic partnerships KE...

LEXXW - Lexaria Announces Issuance of Options

(TheNewswire) Kelowna, British Columbia – TheNewswire – June 8, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global ...

LEXXW - Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1

Dosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria's Patented Technology for Hypertension Relief Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation Second Human Clinical Study, Hyper-H21-2, To Commence Immediat...

LEXXW - Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus

KELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19 SAR...

LEXXW - Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever

New formulation delivers up to 2,708% more CBD into bloodstream* Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innov...

LEXXW - Lexaria Strengthens its International Patent Portfolio to 19 Patents Granted

(TheNewswire) New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia Kelowna, British Columbia – TheNewswire - May 12, 2021 – Lexaria Bioscience Corp. (Nasd...

LEXXW - Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted

New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia KELOWNA, BC / ACCESSWIRE / May 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in dru...

LEXXW - Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET

Lexaria Recently Announced Favorable Data on Its First Animal Study, As Well as the Commencement of Its First Human Clinical Study, Under Its 2021 Hypertension R&D Program KELOWNA, BC / ACCESSWIRE / May 7, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Co...

Previous 10 Next 10